Novan

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline includes SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novan develops products that tap the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. They use its proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. The company is committed to using the power of the human body to create safe and effective treatments. They complement their internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions. It was incorporated in 2008 and is based in Morrisville, North Carolina.

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Novan, Inc. (NASDAQ: NOVN). If you are a...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Novan, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the January 11th-14th H.C. Wainwright BioConnect 2021 Virtual Conference.

Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing –

Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program

– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 –

Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

– T rading on Nasdaq Capital Market is expected to begin on November 5, 2020 –

Novan Receives Approval to Transfer to Nasdaq Capital Market

– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 –

Novan Reports Third Quarter 2020 Financial Results and Provides Corporate Update

- Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET - Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET

Novan to Present at the Virtual Investor KOL Roundtable

- F irst demonstration of antiviral effect of nitric oxide -based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium

Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model

-  John M. Gay , V ice  P resident , Finance and Corporate Controller with over 20 years of financial and accounting experience  appointed as Chief Financial Officer

Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors

- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -

Novan Provides Pipeline and Priority Development Programs Update

- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT -

Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

- Topline results targeted for Q2 2021, less than a year away -

Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

- Clinical sites actively enrolling patients -

Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

MORRISVILLE, N.C., July  28, 2020  (GLOBE NEWSWIRE) --  Novan, Inc.  ("the Company" or "Novan") (Nasdaq: NOVN), today announced an expanded role of  Paula Brown Stafford, President and Chief Executive Officer  (“CEO”) of Novan, to also include Chairman of Novan’s Board of Directors (“Board”). Concurrently, Robert Ingram is retiring as Executive Chairman and will continue as a member of the Board. These changes to the Board are effective as of today, July 28, 2020.

Novan President and CEO, Paula Brown Stafford Named Chairman of the Board

MORRISVILLE, N.C., July  23, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annual Meeting of Stockholders ("ASM") on Tuesday, July 28, 2020 at 9:30 a.m. Eastern Time.

Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders

MORRISVILLE, N.C., June  25, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be sufficient to fund costs associated with conducting an additional Phase 3 pivotal trial for SB206 as a treatment for molluscum, or B-SIMPLE4 (Berdazimer Sodium In Molluscum Patients with Lesions). Since June 1, 2020, the Company has secured approximately $16.9 million in capital from the use of common stock purchase agreements with Aspire Capital Fund, LLC and the exercise of common stock warrants sold in its March 2020 public offering.

Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial

MORRISVILLE, N.C., June  24, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive Officer, will present a corporate overview at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 2:00 p.m. Eastern.

Novan to Present at Virtual Life Sciences Investor Forum on June 25

MORRISVILLE, N.C., April  30, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has received meeting minutes from the April 1, 2020 Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding SB206 for the treatment of molluscum contagiosum (“molluscum”). Based on guidance the Company received during the meeting and subsequently contained within the meeting minutes, Novan is preparing to conduct one additional pivotal trial (“B-SIMPLE4”), which, if successful, could be supported by the previously completed B-SIMPLE2 trial in a future New Drug Application (“NDA”). In addition, the FDA provided guidance with regard to the study design for B-SIMPLE4 and expectations for a future NDA submission, which has been incorporated in the B-SIMPLE4 preliminary trial design characteristics:

Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206

MORRISVILLE, N.C., April  20, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that it has engaged H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) to assist the Company in exploring and evaluating a range of strategic and financial alternatives, intended to maximize shareholder value.

Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives

MORRISVILLE, N.C., April  03, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding SB206 for the treatment of molluscum. The purpose of the meeting was to seek FDA feedback on the proposal to conduct one additional, well-controlled confirmatory study of SB206 to support a future New Drug Application (“NDA”).

Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement

Aytu BioScience

DHT Holdings

Euronav

Top Ranked Momentum Stocks to Buy for April 2nd

MORRISVILLE, N.C., March  26, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct offering priced at-the-market under Nasdaq rules with several institutional and accredited investors of 18,604,652 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at an effective purchase price of $0.43 per share (or pre-funded warrant).

Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

MORRISVILLE, N.C., March  24, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of 18,604,652 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at an effective purchase price of $0.43 per share (or pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules.

Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market

MORRISVILLE, N.C., March  23, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced data from the prospectively planned safety evaluation through Week 24 as part of the Company’s Phase 3 B-SIMPLE program with SB206 for the treatment of molluscum contagiosum (“molluscum”). Top-line efficacy results from the B-SIMPLE program were announced in January 2020 with additional efficacy and safety analyses through Week 12 announced in February 2020.

News for Novan Stock (NOVN)